Cellectis welcomes Axel-Sven Malkomes and Dr. Donald Bergstrom to its Board of Directors

– USA, NY –  Cellectis (NASDAQ: CLLS | EPA: ALCLS), a clinical-stage biotechnology company, today announced the appointments of Axel-Sven Malkomes and Dr. Donald Bergstrom (M.D., Ph.D.) to its Board of Directors, effective immediately.

“We are pleased to continue our work with Dr. Bergstrom and to welcome Mr. Malkomes to the Cellectis Board. They are both seasoned leaders within the healthcare industry, who bring decades of experience in both the healthcare and financial services sectors to Cellectis. We are confident they will provide meaningful and valued perspectives as we continue to progress toward becoming one of the few end-to-end cell and gene therapy companies,” said Dr. André Choulika, Chief Executive Officer.

Dr. Donald A Bergstrom

Dr. Bergstrom was appointed as a Board Observer on the Board of Directors on November 4, 2021.

Dr. Bergstrom currently serves as EVP, Head of Research and Development at Relay Therapeutics, Inc., a clinical-stage precision medicines company. He brings with him over 15 years of experience in the biopharmaceutical and medical industries.

Before his tenure at Relay Therapeutics, Dr. Bergstrom was CMO at Mersana Therapeutics, where he led the advancement of two products based on Mersana’s proprietary antibody-drug conjugate platform through non-clinical development and into Phase 1 clinical trials. Before Mersana, he was Global Head of Translational and Experimental Medicine at Sanofi Oncology. At Sanofi, Dr. Bergstrom held roles of increasing responsibility at Merck Research Laboratories, culminating in his role as Oncology Franchise Lead, Experimental Medicine.

Dr. Bergstrom holds an M.D. from the University of Washington, Seattle, and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed his post-doctoral training. He was a resident in clinical pathology at the University of Washington.

About Axel-Sven Malkomes

Axel-Sven Malkomes served as CFO and CBO at Medigene AG, a clinical stage immuno-oncology company focusing on the development of T-cell immunotherapies for the treatment of cancer, until March 31st, 2022. He brings with him over 25 years of experience in the healthcare sector.

Previous to his tenure at Medigene, Mr. Malkomes served as Vice-Chairman and MD of the Life Sciences Practice for the British bank Barclays in Europe. Before joining Barclays, he was Global Head of Healthcare & Chemicals Investment Banking at the French corporate and investment bank Société Générale.

On the investor side, Mr. Malkomes has accumulated relevant experience during his several years with the UK-listed private equity firm 3i plc. as co-head of European Healthcare Investments. Previously, he had leading operational and corporate roles at the German pharmaceutical company Merck KGaA, i.e. as Head of Strategic Planning as well as Head of Mergers & Acquisitions/Business Development, where he significantly participated in the initial set-up and build-out of the company’s oncology business.

During his international management career, Mr. Malkomes gained extensive knowledge of the pharmaceutical industry.

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene-editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma.HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies, and lysosomal storage diseases. Cellectis’ headquarters are in Paris, France, with locations in New York, New York, and Raleigh, North Carolina.

For more information: https://www.cellectis.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team